checkAd

    3D Druck, allgemein - 500 Beiträge pro Seite (Seite 2)

    eröffnet am 14.03.15 15:42:54 von
    neuester Beitrag 06.04.19 05:12:51 von
    Beiträge: 540
    ID: 1.209.380
    Aufrufe heute: 6
    Gesamt: 14.246
    Aktive User: 0


    Umfrage: Ist der 3D Druck eine ernsthafte Branche, wird er zukünftig größeren Einfluss auf unser Leben haben?

    Nehmen Sie teil und stimmen Sie ab:
    24 Stimmen wurden bereits abgegeben.
    • 1. Ja
    • 2. Nein
    • 3. werden wir sehen
    • 4. wann können die endlich Hamburger machen?
    • 83%
    • 8%
    • 4%
    • 4%
     Durchsuchen
    • 2

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 16.01.19 13:54:20
      Beitrag Nr. 501 ()
      Avatar
      schrieb am 16.01.19 19:27:06
      Beitrag Nr. 502 ()
      Avatar
      schrieb am 17.01.19 22:01:40
      Beitrag Nr. 504 ()
      Avatar
      schrieb am 18.01.19 02:22:56
      Beitrag Nr. 505 ()

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 23.01.19 18:38:06
      Beitrag Nr. 506 ()
      Avatar
      schrieb am 24.01.19 12:24:51
      Beitrag Nr. 507 ()
      1 Antwort
      Avatar
      schrieb am 24.01.19 12:53:09
      Beitrag Nr. 508 ()
      Antwort auf Beitrag Nr.: 59.700.786 von Popeye82 am 24.01.19 12:24:51
      Avatar
      schrieb am 25.01.19 06:43:15
      Beitrag Nr. 509 ()




      1 Antwort
      Avatar
      schrieb am 25.01.19 08:42:11
      Beitrag Nr. 510 ()
      Antwort auf Beitrag Nr.: 59.707.134 von Popeye82 am 25.01.19 06:43:15


      Avatar
      schrieb am 26.01.19 19:58:20
      Beitrag Nr. 511 ()
      world'S FIRST (AND only), personalized, micro-3D printed face mask, delivered right to your door




      www.jnj.com/innovation/neutrogena-unveils-neutrogena-maskid-…



      www.neutrogena.com/maskid

      www.jnj.com/tag/johnson-johnson-consumer-inc
      Avatar
      schrieb am 29.01.19 20:43:16
      Beitrag Nr. 512 ()
      Avatar
      schrieb am 30.01.19 05:06:23
      Beitrag Nr. 513 ()
      3D printed artificial nose, that can smell, any, sort of odour, including noxious substances, like natural gas, ammonia, or sewage







      https://news.ok.ubc.ca/2019/01/24/ubc-researchers-develop-hi…
      https://engineering.ok.ubc.ca/
      http://atfl.ok.ubc.ca/
      http://www.sciencedaily.com/releases/2019/01/190124124739.ht…



      http://www.ubc.ca/
      Avatar
      schrieb am 01.02.19 04:40:12
      Beitrag Nr. 514 ()
      Antwort auf Beitrag Nr.: 59.060.680 von Popeye82 am 26.10.18 02:59:58
      http://stockhead.com.au/tech/titanium-3d-printer-titomic-isn…
      Avatar
      schrieb am 02.02.19 23:32:15
      Beitrag Nr. 515 ()
      1 Antwort
      Avatar
      schrieb am 03.02.19 13:43:03
      Beitrag Nr. 516 ()
      Avatar
      schrieb am 05.02.19 03:02:08
      Beitrag Nr. 517 ()
      Antwort auf Beitrag Nr.: 59.778.168 von Popeye82 am 02.02.19 23:32:15
      http://www.rdmag.com/news/2019/02/3d-printing-technique-uses…
      Avatar
      schrieb am 07.02.19 20:38:25
      Beitrag Nr. 518 ()













      http://viterbischool.usc.edu/news/2019/02/broke-your-shoe-wh…

      - 3D-printed self-healing soft actuator lifts weight, after being cut in half
      1.028 Aufrufe
      1
      0
      Teilen
      Speichern
      USCViterbi
      Am 01.02.2019 veröffentlicht
      Assistant Professor Qiming Wang and his team created a 3D-printed rubber material that is able to repair itself after breaking. Here, the material was used for a soft robotic actuator that is able to lift a weight before and after being cut in half.

      Learn more about it here: https://www.nature.com/articles/s4142...
      Kategorie
      Wissenschaft & Technik -



      http://viterbischool.usc.edu/
      Avatar
      schrieb am 09.02.19 15:54:15
      Beitrag Nr. 519 ()
      Avatar
      schrieb am 09.02.19 17:46:13
      Beitrag Nr. 520 ()
      Avatar
      schrieb am 12.02.19 19:35:19
      Beitrag Nr. 521 ()
      Avatar
      schrieb am 16.02.19 12:02:01
      Beitrag Nr. 522 ()
      Avatar
      schrieb am 16.02.19 20:33:08
      Beitrag Nr. 523 ()
      1 Antwort
      Avatar
      schrieb am 16.02.19 21:30:55
      Beitrag Nr. 524 ()
      Antwort auf Beitrag Nr.: 59.892.043 von Opa_Klaus am 16.02.19 20:33:08Hallo Opa

      Hast Du davon vielleicht auch nochmal ein YouTube Video,
      zum Hier posten?


      Sieht beeindruckend aus.
      Avatar
      schrieb am 16.02.19 21:45:34
      Beitrag Nr. 525 ()
      Avatar
      schrieb am 23.02.19 21:54:32
      Beitrag Nr. 526 ()
      Avatar
      schrieb am 25.02.19 13:36:17
      Beitrag Nr. 527 ()
      Avatar
      schrieb am 26.02.19 02:29:27
      Beitrag Nr. 528 ()
      " Regenerative medicine and 3D bio-printing company Koligo Therapeutics to undertake IPO and list on the ASX




      Koligo Therapeutics, Inc. (“Koligo”) is a US regenerative medicine company developing and commercializing a range of three-dimensional (3D) bio-printed cell and tissue therapies for unmet medical needs.

      Koligo is unique in that, unlike most biotechnology companies, it has a product that is qualified for sale in the United States. Its first product Kyslecel™ is an autologous (meaning the patient’s own cells are used) pancreatic islet cell therapy used to treat chronic or recurrent acute pancreatitis, a debilitating and painful condition with few effective treatment options. Koligo commenced sales of Kyslecel™ in November 2017, generating approximately A$1.6 million in revenue in the recent 14 months, from a limited number of its initial hospital customers. Short-term, Koligo is working on expanding its sales to a larger number of hospitals throughout the United States.




      To make Kyslecel™, the surgeon at a qualified hospital removes the patient’s diseased pancreas (the source of pain and inflammation) and sends it to Koligo’s U.S. Food and Drug Administration (FDA)-registered facility in Louisville, Kentucky. Koligo isolates the pancreatic islets and uses them to produce Kyslecel™. Koligo then ships Kyslecel™ back to the surgeon for re-infusion into the patient’s liver, where the islets are intended to engraft and produce insulin needed to regulate blood sugar. The procedure, combined with the product, reduces the risk of diabetes, has favorable safety and efficacy rates, reduces pain, increases quality of life, and reduces dependency on insulin drugs.


      - The diagram above shows how Kyslecel is used. -


      Koligo is also working on launching Kyslecel V2.0 by mid-2019. This next generation of the product is expected to have an extended shelf life and will therefore allow for wider geographic distribution and potential international marketing opportunities. India and China are also among the countries with large numbers of pancreatitis sufferers, and Koligo is also planning to enter other international markets, potentially through out-licensing and partnerships with established market participants, subject to the receipt of all relevant regulatory approvals.

      Kyslecel™ and Kyslecel V2.0 are only the first steps in Koligo’s development. Koligo is also developing a pipeline of other regenerative medicine products utilising its 3D bio-printing platform which is subject to the completion of its development, clinical testing and regulatory approval. This pipeline (in pre-clinical stages of development) includes novel engineered tissue products containing pancreatic islets for the treatment of pancreatitis, type 1 diabetes, and other pancreatic diseases; as well as 3D printed pre-vascularised cell/tissue structures for multiple indications, including liver failure, neurological diseases, metabolic disorders, and genetic disorders.


      - Koligo’s short to medium-term Product Pipeline -



      - Koligo’s longer-term Project Pipeline -


      Oversimplifying somewhat, the pre-vascularised cell/tissue structures are 3D bio-printed for transplantation into humans with blood vessels already embedded in the tissue.


      - Images (clockwise from top L to R) Spheriods being bio-printed, islets that have re-vascularised, magnified images of bio-printed spheroid containing islets. -


      Koligo Therapeutics Limited (pending ASX code: KOL) (the “Company”), an Australian company which has agreed to acquire Koligo, is conducting the IPO of the business going forward. The Company has lodged a Replacement Prospectus with the Australian Securities and Investments Commission to raise up to A$7 million.

      In the Australian public markets, there have been several successful IPOs of regenerative medicine businesses including Cynata Therapeutics (ASX:CYP) and Polynovo (ASX:PNV), which listed at market capitalisations of less than A$30 million, and now have market capitalisations in excess of A$200 million and A$350 million respectively. Most recently, another regenerative medicine company, Exopharm (ASX:EX1) listed in December 2018, with its share price more than doubling following the listing and remaining at that level, with a market capitalisation of A$20 million. Given Koligo’s focus on 3D bio-printing, of relevance is the fact that the ASX is also home to the successful 3D-printing company Titomic (ASX:TTT) with a current market capitalisation of over A$500 million (up from the initial market capitalisation of less than A$50 million). Uniquely, Koligo is expected to be the only ASX-listed 3D bio-printing company, however 3D bio-printing companies in public markets outside of Australia have enjoyed considerable success.

      The Company’s team is comprised of proven individuals with extensive experience in emerging technologies, commercialising and marketing products, regenerative medicine and in the bio-technology industry; it includes Peter James (Chairman) whose experience includes that of the current Chair of ASX-listed companies Keytone Dairy Corporation Ltd (ASX:KTD) and Nearmap Ltd (ASX:NEA). Koligo’s Executive Director, CEO and co-founder Matthew Lehman was CEO of Prima Biomed Ltd (now Immutep), a dual-listed public company (ASX:PRR (now IMM) and NASDAQ:PBMD (now IMMP)) developing cancer immunotherapies, where he obtained “Fast Track” from the FDA and “Orphan Drug” designation for Prima Biomed’s lead product at the time. Stuart Williams, PhD, (Executive Director and Chief Technology Officer) is a cell biologist and bioengineer with decades of industry and entrepreneurial experience, more than 23 issued patents, and 400+ peer-reviewed publications and the Endowed Chair of Cardiovascular Innovation and Director of the Bioficial Organs Program at the University of Louisville. Balamurugan Appakalai, PhD (Chief of Manufacturing) is a well-recognized pioneer in islet isolation technology and has processed 800+ human pancreases. Mike Hughes, MD (Chief Medical Officer) started the clinical islet transplant program at the Jewish Hospital in Louisville, Kentuck.


      - Images (from L to R): Koligo technician preparing pancreas for islet isolation, transplantation of Kyslecel™ into a patient’s liver, and Kyslecel™ transfusion bag. -"

      http://www.onmarket.com.au/offers/koligo-therapeutics-ltd/?r…
      http://koligo.net/investors/prospectus/
      http://koligo.net/
      Avatar
      schrieb am 01.03.19 17:51:59
      Beitrag Nr. 529 ()
      Avatar
      schrieb am 01.03.19 21:41:51
      Beitrag Nr. 530 ()
      Avatar
      schrieb am 03.03.19 13:38:29
      Beitrag Nr. 531 ()
      Elon Musk, quote: "3D drucken ist tot, 12D is the FUTURE"


      http://www.fabbaloo.com/blog/2019/3/1/four-ways-4d-printing-…
      Avatar
      schrieb am 10.03.19 22:52:57
      Beitrag Nr. 532 ()
      Avatar
      schrieb am 15.03.19 03:25:31
      Beitrag Nr. 533 ()
      Avatar
      schrieb am 16.03.19 20:25:24
      Beitrag Nr. 534 ()
      Avatar
      schrieb am 23.03.19 14:10:42
      Beitrag Nr. 535 ()

      http://3dprintingindustry.com/news/allevi-launches-bioink-ki…



      http://allevi3d.com/
      Avatar
      schrieb am 27.03.19 03:12:32
      Beitrag Nr. 536 ()
      Avatar
      schrieb am 27.03.19 13:13:10
      Beitrag Nr. 537 ()
      Avatar
      schrieb am 27.03.19 13:54:24
      Beitrag Nr. 538 ()
      Avatar
      schrieb am 30.03.19 17:25:41
      Beitrag Nr. 539 ()
      Avatar
      schrieb am 06.04.19 05:12:51
      Beitrag Nr. 540 ()
      • 2
       Durchsuchen


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      3D Druck, allgemein